280 related articles for article (PubMed ID: 30901389)
1. A New Ophthalmic Pharmaceutical Formulation, Topical Sulglycotide, Enhances the Ocular Mucin Secretion in Desiccation Stress-Mediated Dry Eye Disease.
Lee H; Jeon S; Kim CE; Park YJ; Yang J
Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1076-1087. PubMed ID: 30901389
[TBL] [Abstract][Full Text] [Related]
2. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Shamloo K; Barbarino A; Alfuraih S; Sharma A
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Efficacy of Nanocomplex of Poly(Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model.
Lee H; Shim W; Kim CE; Choi SY; Lee H; Yang J
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1682-1691. PubMed ID: 28319642
[TBL] [Abstract][Full Text] [Related]
4. Effects of Topical Mucolytic Agents on the Tears and Ocular Surface: A Plausible Animal Model of Mucin-Deficient Dry Eye.
Li X; Kang B; Woo IH; Eom Y; Lee HK; Kim HM; Song JS
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3104-3114. PubMed ID: 30025127
[TBL] [Abstract][Full Text] [Related]
5. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Moon I; Kang HG; Yeo A; Noh H; Kim HC; Song JS; Ji YW; Lee HK
J Ocul Pharmacol Ther; 2018 Nov; 34(9):612-620. PubMed ID: 30325678
[TBL] [Abstract][Full Text] [Related]
7. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model.
Kim CE; Kim YJ; Hwang MW; Park YJ; Yang J
Biomed Pharmacother; 2021 Jul; 139():111571. PubMed ID: 33857915
[TBL] [Abstract][Full Text] [Related]
8. Effects of DA-6034 on aqueous tear fluid secretion and conjunctival goblet cell proliferation.
Choi SM; Lee YG; Seo MJ; Kang KK; Ahn BO; Yoo M
J Ocul Pharmacol Ther; 2009 Jun; 25(3):209-14. PubMed ID: 19456255
[TBL] [Abstract][Full Text] [Related]
9. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress.
Yoon KC; Ahn KY; Choi W; Li Z; Choi JS; Lee SH; Park SH
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7267-73. PubMed ID: 21849424
[TBL] [Abstract][Full Text] [Related]
10. Effects of Quercetin in a Mouse Model of Experimental Dry Eye.
Oh HN; Kim CE; Lee JH; Yang JW
Cornea; 2015 Sep; 34(9):1130-6. PubMed ID: 26203745
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye.
Qu M; Qi X; Wang Q; Wan L; Li J; Li W; Li Y; Zhou Q
Invest Ophthalmol Vis Sci; 2019 Sep; 60(12):3776-3785. PubMed ID: 31503282
[TBL] [Abstract][Full Text] [Related]
12. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
13. Effect of Retinol Palmitate on Corneal and Conjunctival Mucin Gene Expression in a Rat Dry Eye Model After Injury.
Tabuchi N; Toshida H; Koike D; Odaka A; Suto C; Ohta T; Murakami A
J Ocul Pharmacol Ther; 2017; 33(1):24-33. PubMed ID: 28009531
[TBL] [Abstract][Full Text] [Related]
14. Effects of silk fibroin in murine dry eye.
Kim CE; Lee JH; Yeon YK; Park CH; Yang J
Sci Rep; 2017 Mar; 7():44364. PubMed ID: 28281688
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
16. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
17. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
18. Secreted Mucins on the Ocular Surface.
Hori Y
Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES151-DES156. PubMed ID: 30481820
[TBL] [Abstract][Full Text] [Related]
19. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
[TBL] [Abstract][Full Text] [Related]
20. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome.
Argüeso P; Balaram M; Spurr-Michaud S; Keutmann HT; Dana MR; Gipson IK
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1004-11. PubMed ID: 11923240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
